Phase II trial of fludarabine phosphate in multiple myeloma using a loading dose and continuous infusion schedule Academic Article uri icon

Overview

MeSH Major

  • B-Lymphocytes
  • Genes, Immunoglobulin
  • Immunoglobulin Light Chains
  • Immunoglobulin Variable Region
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Mutation

abstract

  • A phase II trial of fludarabine phosphate using a bolus and continuous infusion regimen in previously treated multiple myeloma was performed. No responses were observed in eleven patients. There was no significant non-hematologic toxicity noted. Fludarabine phosphate is inactive in multiple myeloma using this schedule.

publication date

  • January 1991

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3109/10428199109064880

PubMed ID

  • 27457577

Additional Document Info

start page

  • 61

end page

  • 3

volume

  • 6

number

  • 1